CMV virus reactivation in kids after stem cell transplant
Part of Infections clinical trials.
This study looks at how often a common virus (CMV) becomes active again in children after a stem cell transplant from a donor. It will help doctors understand more about this risk and how to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child was younger than 18 when they had their stem cell transplant.
- Your child had their transplant between January 2018 and June 2020.
- Your child has never been treated with the drug Letermovir.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
This study looks at how well a new blood test detects cytomegalovirus (a common virus) in people who have had a stem cell transplant. The test may help doctors catch the virus early and treat it faster.
This study checks whether certain virus levels in your blood after a stem cell transplant can help predict or prevent CMV infection. It aims to improve how doctors monitor and protect patients from this virus.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
This study looks at how your immune system recovers after a stem cell transplant and whether that affects your risk of getting a late cytomegalovirus (CMV) infection. You will take letermovir, a medicine that helps prevent CMV, and the study will check your immune function when you stop taking it.
Hear when a new Cytomegalovirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.